AbbVie inks deal with Parvus; Sofinnova invests in Cure51

Plus, news about Aque­s­tive Ther­a­peu­tics and Cy­bin:

Ab­b­Vie en­lists Parvus Ther­a­peu­tics for IBD pact: Ab­b­Vie will have the op­tion to de­vel­op and com­mer­cial­ize Parvus’ ther­a­pies for in­flam­ma­to­ry bow­el dis­eases (IBD). Parvus’ ther­a­pies trig­ger T cells to grow and turn in­to reg­u­la­to­ry T cells — a spe­cial­ized type of T cell that can sup­press the im­mune sys­tem.

The deal adds an­oth­er pipeline op­tion to Ab­b­Vie’s IBD fran­chise, which in­cludes Rin­voq and Skyrizi. And it adds to Parvus’ list of phar­ma col­lab­o­ra­tors, which in­clude No­var­tis and Roche’s Genen­tech. Fi­nan­cial de­tails of the li­cens­ing deal were not dis­closed, though Parvus could re­ceive a po­ten­tial eq­ui­ty in­vest­ment from Ab­b­Vie. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.